Half Year 2021 Biocon Ltd Earnings Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Neha Manpuria - JPMorgan Chase & Co, Research Division - Analyst : My first question is, I think in the opening remarks, you mentioned some sort of a supply (inaudible) your top line. If you could give more color on that? And if you could quantify what was the impact because of the supply constraints?

Question: Neha Manpuria - JPMorgan Chase & Co, Research Division - Analyst : I'm not sure I understand that. When you say limited capacity to meet a higher demand, given our expansion in peg and available capacity for trastuzumab, which I'm assuming are the 2 largest products and insulin, what do you mean by -- if you could just give a little more -- just to understand it better, what gives us the confidence that this will get resolved in the coming quarters?

Question: Neha Manpuria - JPMorgan Chase & Co, Research Division - Analyst : Understood. And Chinni, could you quantify what in your assessment would be the impact because of this? And by when do we expect this to normalize? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. OCTOBER 23, 2020 / 3:30AM, BION.NS - Half Year 2021 Biocon Ltd Earnings Call

Question: Neha Manpuria - JPMorgan Chase & Co, Research Division - Analyst : Understood. My second question is, while I understand that COVID has impacted patient flow into hospitals, if I were to look at data for some of our competitor products in both peg and trastuzumab, they seem to be showing a positive momentum in terms of market share. While we have seen it in Fulphila and Ogivri, is there any reason -- or just wanted some color on what's making the ramp-up slower despite having additional capacity, despite our competitors still seeing greater market share.

Question: Neha Manpuria - JPMorgan Chase & Co, Research Division - Analyst : Okay. And any reason why our market share ramp-up in the U.S. has been gradual? Or to rephrase the question, how is it tracking versus our expectation after the additional capacity approval?

Question: Nitin Agarwal - IDFC Securities Limited, Research Division - Analyst : Christiane, as the biosimilar market is now beginning to open up with more sort of follow-on approvals coming through across different products, I just wanted to -- what's your sense in terms of how important is the first-mover advantage in your assessment in these products? Or given the nature of these products, that's not going to be a relevant force from a market share sort of structuring perspective in the coming quarters, I mean, as we go forward with it? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. OCTOBER 23, 2020 / 3:30AM, BION.NS - Half Year 2021 Biocon Ltd Earnings Call

Question: Nitin Agarwal - IDFC Securities Limited, Research Division - Analyst : Okay. That's helpful. And secondly, on the emerging market biologics business, I mean, have you seen any different dynamics in terms of [versus regulated] markets? Is it easy to scale up products in these markets versus what U.S. and Europe have sort of experienced over the last few years of their initial biologics experience?

Question: Nitin Agarwal - IDFC Securities Limited, Research Division - Analyst : That's helpful. Quickly, if I can add on to that, in the developed markets, is there a way -- is bulk of the business, which comes from biologics,

Question: Charulata Gaidhani - Dalal & Broacha Stock Broking Pvt Ltd., Research Division - Analyst : Yes. My question pertains to -- for Aspart, have you got a target date?

Question: Charulata Gaidhani - Dalal & Broacha Stock Broking Pvt Ltd., Research Division - Analyst : Okay. Yes. Then secondly, in terms of the CapEx over the next 2 years, could you give me the segment-wise breakup in terms of biologics how much, generics and Syngene?

Question: Charulata Gaidhani - Dalal & Broacha Stock Broking Pvt Ltd., Research Division - Analyst : Okay. Yes. And last question on remdesivir, are we looking at exports to the...

Question: Charulata Gaidhani - Dalal & Broacha Stock Broking Pvt Ltd., Research Division - Analyst : Okay. But the current agreement is only for LMIC, right?

Question: Charulata Gaidhani - Dalal & Broacha Stock Broking Pvt Ltd., Research Division - Analyst : Okay. Yes. So U.S. doesn't look likely?